ABBVAbbVie
$276.40+27% 1Y
$276.40
$197.3852 weeks$276.40
Latest close: a new 52-week highOct 9, 2026what changed →
The financials
AbbVie by the numbers
AbbVie (ABBV) reported revenue of $17.0B in Q2 2026 (quarter ended Jun 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 75% and net income of $3.61B (21% of revenue). For the full year FY2025, revenue was $61.2B (+8.6% year on year) and net income $4.23B. Its largest product in Q2 2026 was SKYRIZI at $4.77B, 36% of the disclosed total, well ahead of RINVOQ at 13%. The next results filing is expected around Jan 6, 2027, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $17.0B | $15.4B | +10% |
| Gross profit | $12.7B | $11.1B | +15% |
| Operating income | $6.43B | $4.89B | +31% |
| Net income | $3.61B | $938M | +285% |
| Diluted EPS | $2.03 | $0.52 | +290% |
| Product | Revenue | Share |
|---|---|---|
| SKYRIZI | $4.77B | 36% |
| RINVOQ | $1.76B | 13% |
| Other Products | $1.11B | 8.3% |
| Vraylar | $1.07B | 8.0% |
| Botox Therapeutic | $864M | 6.5% |
| HUMIRA | $425M | 3.2% |
| Botox Cosmetic | $400M | 3.0% |
| Ubrelvy | $379M | 2.9% |
| VENCLEXTA | $369M | 2.8% |
| Creon | $345M | 2.6% |
| Imbruvica | $337M | 2.5% |
| Qulipta | $289M | 2.2% |
| Linzess Constella | $283M | 2.1% |
| Other Aesthetics | $258M | 1.9% |
| Elahere | $161M | 1.2% |
| MAVYRET | $133M | 1.0% |
| Vyalev | $128M | 1.0% |
| Juvederm Collection | $103M | 0.8% |
| Other Neuroscience | $43M | 0.3% |
| Epkinly | $39M | 0.3% |
| Other Oncology | $33M | 0.2% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $13.30B (+16%)
Other Oncology grew +1550% year on yearHUMIRA -47% year on year
Segment Latestquarter on quarteryear on year
- SKYRIZI$4.77B$4.77Bquarter on quarter +26%year on year +24%+26%+24%
- RINVOQ$1.76B$1.76Bquarter on quarter +26%year on year +22%+26%+22%
- Other Products$1.11B$1.11Bquarter on quarter +8.2%year on year -0.72%+8.2%-0.72%
- Vraylar$1.07B$1.07Bquarter on quarter +18%year on year +19%+18%+19%
- Botox Therapeutic$864.0M$864.0Mquarter on quarter +2.6%year on year +11%+2.6%+11%
- HUMIRA$425.0M$425.0Mquarter on quarter +19%year on year -47%+19%-47%
- Botox Cosmetic$400.0M$400.0Mquarter on quarter +7.8%year on year -2.4%+7.8%-2.4%
- Ubrelvy$379.0M$379.0Mquarter on quarter +15%year on year +15%+15%+15%
- VENCLEXTA$369.0M$369.0Mquarter on quarter +8.2%year on year +15%+8.2%+15%
- Creon$345.0M$345.0Mquarter on quarter -4.4%year on year -15%-4.4%-15%
- Imbruvica$337.0M$337.0Mquarter on quarter +1.5%year on year -38%+1.5%-38%
- Qulipta$289.0M$289.0Mquarter on quarter +16%year on year +22%+16%+22%
- Linzess Constella$283.0M$283.0Mquarter on quarter +4.0%year on year +15%+4.0%+15%
- Other Aesthetics$258.0M$258.0Mquarter on quarter +4.0%year on year -8.5%+4.0%-8.5%
- Elahere$161.0M$161.0Mquarter on quarter +0.63%year on year +17%+0.63%+17%
- MAVYRET$133.0M$133.0Mquarter on quarter -27%year on year -28%-27%-28%
- Vyalev$128.0M$128.0Mquarter on quarter +44%year on year +482%+44%+482%
- Juvederm Collection$103.0M$103.0Mquarter on quarter +21%year on year -1.9%+21%-1.9%
- Other Neuroscience$43.0M$43.0Mquarter on quarter -6.5%year on year -39%-6.5%-39%
- Epkinly$39.0M$39.0Mquarter on quarter +22%year on year +86%+22%+86%
- Other Oncology$33.0M$33.0Mquarter on quarter +38%year on year +1550%+38%+1550%
Drug Manufacturers, General
The closest names by size in the same industry